DT2216 is a VHL-recruiting BCL-XL PROTAC. An original 2025 Phase 1 paper in 20 patients reports human PK and peripheral leukocyte BCL-XL reduction. NCI lists combination studies in ovarian and fibrolamellar liver cancers.
2021-08-20 · CPRIT product development research grant · $14.4 million research grant ↗
Not counted as Series A/B or other equity financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
DT2216 is a VHL-recruiting BCL-XL PROTAC. An original 2025 Phase 1 paper in 20 patients reports human PK and peripheral leukocyte BCL-XL reduction. NCI lists combination studies in ovarian and fibrolamellar liver cancers.
Program / service
Target / indication
Representative stage
Evidence & scope
DT2216
BCL-XL · See individual trial / indication; not individually confirmed in this review
Phase 1/2
Human results reported by the source; see facts and original materials for type and quality
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
The best overall Phase 1 response was stable disease, with no PR/CR. Thrombocytopenia still occurred, so it should not be described as free of platelet toxicity. Website sections differ on stage; current trials require registry-level verification.
